SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Blackwood MA, Weber BL. BRCA1 and BRCA2 from molecular genetics to clinical medicine. J Clin Oncol. 1998; 16: 19691977.
  • 2
    Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998; 62: 676689.
  • 3
    Lodder L, Frets P, Trijsbrug W, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet. 2001; 98: 1524.
  • 4
    Lodder L, Frets P, Trijsburg R, et al. One-year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcomes and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002; 73: 97112.
  • 5
    Metcalfe K, Liede A, Hoodfar E, Foulkes W, Narod S. An evaluation of needs among female BRCA1 and BRCA2 carriers undergoing genetic counseling. J Med Genet. 2000; 37: 866874.
  • 6
    Wellisch DK, Gritz E, Schain W, Wang H-J, Siau J. Psychological functioning of daughters of breast cancer patients. Psychosomatics. 1991; 32: 324336.
  • 7
    Appleton S, Fry A, Rees G, Rush R, Cull A. Psychosocial effects of living with an increased risk of breast cancer: an exploratory study using telephone focus groups. Psycho-oncology. 2000; 9: 511521.
  • 8
    Wellisch D, Lindberg N. A psychological profile of depressed and nondepressed women at high risk for breast cancer. Psychosomatics. 2001; 42: 324336.
  • 9
    Esplen MJ, Hunter J. Grief in women with a family history of breast cancer. Prim Psychiatry. 2002; 9: 5764.
  • 10
    Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002; 20: 514520.
  • 11
    Dorval M, Patenaude A, Schneider K, et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol. 2000; 18: 21352142.
  • 12
    Croyle R, Smith K, Botkin J, Baty B, Nash J. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol. 1997; 16: 6372.
  • 13
    Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996; 275: 18851892.
  • 14
    Smith KR, West JA, Croyle RT, Botkin JR. Familial context of genetic testing for cancer susceptibility: moderating effects of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev. 1999; 8: 385392.
  • 15
    Audrain J, Schwartz MD, Lerman C, Hughes C, Peshkin BN, Biesecker B. Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med. 1997; 19: 370377.
  • 16
    Tercyak K, Lerman C, Peshkin B, et al. Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk. Health Psychol. 2001; 29: 217222.
  • 17
    Kash K, Ortega-Verdejo K, Dabney M, Holland J, Miller D, Osborne M. Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. Semin Surg Oncol. 2000; 18: 333338.
  • 18
    Hartmann L, Sellers T, Schaid D, et al. Clinical options for women at high risk for breast cancer. Surg Clin North Am. 1999; 79: 11891206.
  • 19
    Eisen A, Rebbeck T, Wood W, Weber B. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000; 18: 19801995.
  • 20
    Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology. 2001; 10: 231241.
  • 21
    Meiser B, Butow P, Friedlander M, et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol. 2000; 18: 22502257.
  • 22
    Lerman C, Peshkin B, Hughes C, Isaacs C. Family disclosure in genetic testing for cancer susceptibility: determinants and consequences. J Health Care Law Policy. 1998; 1: 353373.
  • 23
    Tercyak K, Peshkin B, DeMarco T, Brogan B, Lerman C. Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns. 2002; 47: 145153.
  • 24
    Bonadona V, Saltel P, Desseigne F, et al. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behaviour after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev. 2002; 11: 97104.
  • 25
    Spiegel D, Bloom J, Yalom I. Group support for patients with metastatic cancer: a randomized outcome study. Arch Gen Psychiatry. 1981; 38: 527533.
  • 26
    Spiegel D, Bloom J, Kraemer H, Gottheil S. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; 2: 888291.
  • 27
    Spiegel D, Spira J. Supportive-expressive group therapy: a treatment manual of psychosocial intervention for women with recurrent breast cancer. Sanford, CA: Psychosocial Treatment Laboratory, Stanford University School of Medicine, 1991.
  • 28
    Spiegel D, Classen C. Group therapy for cancer patients: a research-based handbook of psychosocial care. New York: Basic Books, 2003.
  • 29
    Goodwin P, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001; 345: 17191726.
  • 30
    Leszcz M, Goodwin P. The rationale and foundations of group psychotherapy for women with metastatic breast cancer. Int J Group Psychother. 1998; 48: 245273.
  • 31
    Esplen MJ, Toner B, Hunter J, Glendon G, Butler K, Field B. A group therapy approach to facilitate integration of risk information for women at risk for breast cancer. Can J Psychiatry. 1998; 43: 375380.
  • 32
    Horrowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979; 41: 209218.
  • 33
    Lerman C, Lustbader E, Rimer B, et al. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst. 1995; 87: 286292.
  • 34
    Lerman C, Schwartz M, Miller S, Daly M, Sands C, Rimer B. A randomized trial of breast cancer risk counselling: interacting effects of counselling, educational level and coping style. Health Psychol. 1996; 15: 7583.
  • 35
    Horrowitz M, Sundin E, Zanko A, Lauer R. Coping with grim news from genetic tests. Psychosomatics. 2001; 42: 100105.
  • 36
    Lindberg N, Wellisch D. Identification of traumatic stress reactions in women at increased risk for breast cancer. Psychosomatics. 2004; 45: 716.
  • 37
    Derogatis LR. The brief symptom inventory (BSI). Administration, scoring and procedures anual. 3rd edition. New York: National Computer Systems, 1993.
  • 38
    Faschingbauer TR. Texas revised inventory of grief manual. Houston: Honeycomb Publishing Company, 1981.
  • 39
    Ferrans CE, Powers MJ. Quality of life index: development and psychometric properties. ANS Adv Nurs Sci. 1985; 8: 1524.
  • 40
    The Cochrane Collaboration Open Learning Materials for Reviewers: intent to treat analysis. Module 14, page 6. Available from URL: http://www.cochrane-net.org/openlearning/HTML/mod14-4.htm, 2002 [accessed 25 June 2003].
  • 41
    Sundin E, Horowitz M. Horowitz's impact of event scale evaluation of 20 years of use. Psychosom Med. 2003; 65: 870876.
  • 42
    Yalom ID. Theory and practice of group psychotherapy. 4th edition. New York: Basic Books, 1995.
  • 43
    Stiefel F, Lehmann A, Guex P. Genetic detection: the need for psychosocial support in modern cancer prevention. Support Care Cancer. 1997; 5: 461465.
  • 44
    Thewes B, Meiser B, Hickie IB. Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology. 2001; 10: 459468.
  • 45
    Fawzy I, Fawzy NW, Fawzy JG, Wheeler A. Post-hoc comparison of the efficiency of a psychoeducational intervention for melanoma patients delivered in group versus individual formats: an analysis of data from two studies. Psychooncology. 1996; 5: 8189.
  • 46
    Ringdal GI, Jordhoy MS, Ringdal K, Kaasa S. The first year of grief and bereavement in close family members to individuals who have died of cancer. Palliat Med. 2001; 15: 91105.
  • 47
    Surtees P, Wainwright N. Surviving adversity: event decay, vulnerability and the onset of anxiety and depressive disorder. Eur Arch Psychiatry Clin Neurosci. 1999; 249: 8695.
  • 48
    Chochinov H, Holland J. Katz L. Bereavement: a special issue in oncology. In: HollandJC, BrentbartW, JacobsenP, et al., editors. Handbook of psychooncology. New York: Oxford University Press, 1998: 10161032.
  • 49
    Bonanno G, Kaltman S. The varieties of grief experience. Clin Psychol Rev. 2001; 21: 705734.
  • 50
    Wellisch DK, Hoffman A, Goldman S, Hammerstein J, Klein K, Bell M. Depression and anxiety symptoms in women at high risk for breast cancer: pilot study of a group intervention. Am J Psychiatry. 1999; 156: 16441645.
  • 51
    Piper W, McCallum M, Azim H. Adaptation to loss through short-term group psychotherapy. New York: Guildford Press, 1992.
  • 52
    O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995; 15: 2530.